logo
logo

Babson Diagnostics Raises $31 Million In Series B Funding To Drive Retailization Of Customer-First, Convenient, And Highly Accessible Diagnostic Blood Testing

Jun 29, 2021•about 4 years ago

Amount Raised

$31 Million

Round Type

series b

Austin

Description

Babson Diagnostics, a transformative medical technology company improving customer access to diagnostic blood testing, today announced the closing of $31 million in an oversubscribed Series B funding round, led by Emerald Development Managers, with full participation by existing investors Siemens Healthineers, Prism Ventures, and Lago Consulting Group.

Company Information

Company

Babson Diagnostics

Location

Austin, Texas, United States

About

Babson Diagnostics aims to democratize diagnostic blood testing by making it easier, faster, and more pleasant for customers to routinely monitor and improve their health. Babson's proprietary technological ecosystem is designed to deliver accurate diagnostic results with a more human experience. Based in Austin, Texas, its vision for diagnostic blood testing — built on accuracy, convenience, and accessibility — combines transformative diagnostic technology with a customer-first, retail-centric business model that aims to improve customer health and experience. Prior to commercialization, Babson Diagnostics is working with retail pharmacies to validate its technology by conducting clinical studies intended for peer-reviewed publication. For more information on Babson Diagnostics, please visit www.babsondx.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech